Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 6,600 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multi Center Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium

NCT00474136
View directory record Official record
Conditions
Healthy
Interventions
Intravenous diclofenac sodium (DIC075V) 18.75 mg, Intravenous diclofenac sodium (DIC075V) 37.5 mg, Oral diclofenac potassium 50 mg
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Nov 7, 2026, 10:37 AM EST
Terminated Phase 2 Interventional

Study of ART0380 in Patients With Biologically Selected Solid Tumors

NCT05798611
View directory record Official record
Conditions
Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer
Interventions
ART0380
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Nov 7, 2026, 10:37 AM EST
Completed No phase listed Observational

Pediatric Locking Nail for the Treatment of Femoral Fractures in Children

NCT00725894
View directory record Official record
Conditions
Femur Fracture
Interventions
Pediatric Locking Nail
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
8 Years to 16 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Phoenix, Arizona • Orlando, Florida • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Nov 7, 2026, 10:37 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

To Show the Safety and Effectiveness of the Demetech Barbed Polydioxanone (PDO) Suture

NCT06404372
View directory record Official record
Conditions
Wrinkle
Interventions
Demetech Barbed PDO Suture
Device
Lead sponsor
Sutura Medical Technology LLC
Industry
Eligibility
22 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Sherman Oaks, California • The Woodlands, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 7, 2026, 10:37 AM EST
Terminated Not applicable Interventional

Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity

NCT04742257
View directory record Official record
Conditions
Muscle Spasticity, Stroke
Interventions
MyoRegulator® device
Device
Lead sponsor
PathMaker Neurosystems Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cambridge, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 3 Interventional Results available

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

NCT00829829
View directory record Official record
Conditions
Intercritical Gout
Interventions
Placebo, Rilonacept 80 mg, Rilonacept 160 mg
Other · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
67
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 4 Interventional Results available

SISTERS: Spasticity In Stroke Study - Randomized Study

NCT01032239
View directory record Official record
Conditions
Severe Spasticity
Interventions
intrathecal baclofen
Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
9
States / cities
Irvine, California • Washington D.C., District of Columbia • Doral, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Nov 7, 2026, 10:37 AM EST
Terminated Phase 2 Interventional

Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

NCT01101945
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 75 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Fullerton, California • Long Beach, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Nov 7, 2026, 10:37 AM EST
Not listed Phase 2 Interventional

A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

NCT00113412
View directory record Official record
Conditions
HIV Infections
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2006 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00674739
View directory record Official record
Conditions
Genital Warts
Interventions
Imiquimod, 3.75% imiquimod cream, placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00657501
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
66
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 2 Interventional Results available

Staccato Prochlorperazine in Migraine (Out Patient)

NCT00422812
View directory record Official record
Conditions
Migraine Headache, Aura
Interventions
Inhaled Placebo, Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Nov 7, 2026, 10:37 AM EST
Completed No phase listed Observational Accepts healthy volunteers

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

NCT02381457
View directory record Official record
Conditions
22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Sex Chromosome Abnormalities, Cri-du-Chat Syndrome, Angelman Syndrome, Prader-Willi Syndrome, 1p36 Deletion Syndrome
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
20,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
16
States / cities
San Francisco, California • Camden, New Jersey • Mount Laurel, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Nov 7, 2026, 10:37 AM EST
Not listed Phase 1Phase 2 Interventional

A Study of ICP-192 in Patients With Advanced Solid Tumors

NCT04565275
View directory record Official record
Conditions
Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
Interventions
Drug ICP-192
Drug
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Tucson, Arizona • La Jolla, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Nov 7, 2026, 10:37 AM EST
Not yet recruiting No phase listed Observational

Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform

NCT07609069
View directory record Official record
Conditions
Drug Related Side Effects and Adverse Reactions, Infusion Reactions
Interventions
PIV-850 (850-picometer Dual-NCE Acidic Matrix), Legacy Heterogeneous Payload (Micellar Vehicle)
Drug
Lead sponsor
PICO IV, Inc.
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 2Phase 3 Interventional Results available

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

NCT02116803
View directory record Official record
Conditions
Solid Tumors
Interventions
dovitinib, fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Las Vegas, Nevada • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 3 Interventional Results available

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT02872103
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
F-627, Placebo
Drug
Lead sponsor
EVIVE Biotechnology
Industry
Eligibility
18 Years to 74 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 3 Interventional

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

NCT00432861
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
PANCRECARB® (pancrelipase), Placebo
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Nov 7, 2026, 10:37 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Multi-Center Randomized Controlled Trial of Mentoring to Prevent Youth Violence

NCT01770873
View directory record Official record
Conditions
Violence
Interventions
Take Charge 2
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 15 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Nov 7, 2026, 10:37 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers

NCT02129569
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Psychoeducational intervention, behavioral intervention, counseling intervention, educational intervention, telephone-based intervention, questionnaire administration, quality-of-life assessment
Other · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Nov 7, 2026, 10:37 AM EST
Terminated No phase listed Observational

Single Position Spine Surgery Registry

NCT04839783
View directory record Official record
Conditions
Spine Fusion, Spinal Stenosis, Degenerative Disc Disease
Interventions
Not listed
Lead sponsor
Spine and Scoliosis Research Associates
Other
Eligibility
18 Years to 100 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Wilmington, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01064622
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 2 Interventional Results available

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

NCT00595231
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
SYN111, Placebo
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Atlanta, Georgia • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Nov 7, 2026, 10:37 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

NCT03821402
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
26
States / cities
Downey, California • Fountain Valley, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 7, 2026, 10:37 AM EST